Celecoxib

• 

  Subject Areas on Research

  • A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. 
  • A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 
  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. 
  • A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. 
  • Celecoxib (celebrex) increases canine lower esophageal sphincter pressure. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Celecoxib does not delay cutaneous wound healing in haemophilia B mice. 
  • Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 
  • Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor. 
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. 
  • Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂. 
  • How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. 
  • Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • ROC curve estimation under test-result-dependent sampling. 
  • Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • The STAMPEDE trial and celecoxib: how to adapt? 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 
  • Utilization of a Preemptive, Multimodal Analgesic Regimen in Adult Ambulatory Septoplasty Patients: A Quality Improvement Project.